While the inhibition of NKCC1 may not be a viable therapeutic target for treatment, further work to elucidate the role of ion transporters in relation to BBB integrity can aid in further knowledge of HE pathogenesis. Here, SLC12A2 is linked to hereditary elliptocytosis.